ArticleThe Indian journal of medical research2026
Stage-specific lipidomic signatures as biomarkers in progression of cervical cancer.
Article in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Lipidomics has advanced cancer research by uncovering biomarkers that reveal key mechanisms of tumourigenesis. By analysing endpoint lipid metabolites influenced by genetic and environmental factors, the lipidome closely reflects a cell's functional state. Mass spectrometry, strengthened by modern bioinformatics and biostatistics, now enables precise detection of cancer-related lipid changes, motivating us to adopt this approach. Methods We have applied advanced mass spectrometry and machine-learning methods to develop a novel tool for cervical cancer screening, the second most common cancer in India. The study included cervical cancer patients diagnosed through cytology, HPV testing, histopathology, or imaging, along with healthy volunteers as controls. Serum samples from all participants were analysed using Ultra High Performance Liquid Chromatography coupled with high-resolution Orbitrap Mass Spectrometry using a targeted approach for lipid biomarker discovery. Results A comprehensive evaluation of controls and cervical cancer patients across clinical stages revealed distinct lipidomic patterns and biomarker differences. We identified a 3-biomarker panel [LPE (22:6)+H, PE (18:1_20:4)+H, and MG (20:0)+H] effective for early-stage detection and a 4-biomarker panel (LPE (22:6)+H, PE (18:1_20:4)+H, PC (16:1_20:5)+H, and TG (16:0_18:1_18:3)+H) suitable for comprehensive cervical cancer screening. The combined ROC for the 3-biomarker panel showed 88% sensitivity, 93% specificity, 90% accuracy, and an area under the curve (AUC) of 0.945, while the 4-biomarker panel achieved 87% sensitivity, 84% specificity, 86% accuracy, and an AUC of 0.946. Interpretation and conclusions Our study demonstrates a clear link between altered lipid metabolism and cervical cancer, paving the way for future research to identify new diagnostic and prognostic markers and ultimately enabling earlier detection and timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.